The illustration depicts how during differentiation cells normally lose their plasticity and ability to acquire new fates.
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
Discover why Lyell Immunopharma (LYEL) stock is up 191% YTD. Explore CAR T therapy breakthroughs, trial milestones, and key investment insights.
Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...
At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...
Zacks Investment Research on MSN
CRSP stock rises on encouraging early data from Zugo-Cel studies
Shares of CRISPR Therapeutics CRSP were up 3.7% yesterday after the company announced encouraging updates from ongoing studies on its next-generation CAR-T therapy candidate, zugocaptagene geleucel or ...
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, ...
CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback